Wedbush Cuts NKTR Target as Options Defensiveness Spikes
Nektar Therapeutics has dropped another 8.5% this week to $60.97, compounding a bruising month that has now erased 17.6% — and the most telling shift from seven days ago is not in the short book but on the Street,…